← All trials
NCT05554822
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Sep 26, 2022
- Last posted
- Oct 3, 2022
- Enrollment
- 574
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Eastern PiedmontLead sponsor
- AbbottCollaborator
- University of Eastern PiedmontReponsible party - principal investigator
- University of Eastern PiedmontStudy director
- University of Eastern PiedmontOfficial
- University of Eastern PiedmontSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.